Breaking News
Get 50% Off 0
🏄 Grow your portfolio even on vacation with InvestingPro | Summer Sale 50% OFF
CLAIM SALE
Close

Jiangsu Asieris Pharmaceuticals Co Ltd (688176)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
11.33 -0.27    -2.33%
07:59:59 - Closed. Currency in CNY
Type:  Equity
Market:  China
ISIN:  CNE100005XW0 
  • Volume: 10,865,563
  • Bid/Ask: 11.33 / 11.34
  • Day's Range: 11.27 - 11.68
Jiangsu Asieris Pharmaceuticals 11.33 -0.27 -2.33%

Jiangsu Asieris Pharmaceuticals Co Ltd Company Profile

 
Get an in-depth profile of Jiangsu Asieris Pharmaceuticals Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

391

Equity Type

ORD

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. Its pipeline includes APL-1202, which is in Phase III clinical trial for the treatment of urinary system tumors; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors; APL-1706, which is in Phase III clinical trial for the treatment of urinary system tumors; and APL-1702, a photodynamic therapy product that is in Phase III clinical trial for the treatment of cervical high-grade squamous intraepithelial lesions of the cervix. In addition, it develops targeted protein degraders which are in preclinical stage comprising ASN-240 and ASN-2304 for the treatment of urinary system tumors; and APL-1901 for the treatment of ER positive breast cancer. Further, the company develops APL-2302 which is in phase I of clinical trial for the treatment of ovarian cancer, breast cancer, etc.; and APL-2501, AT-018, and AT-021 which are in the preclinical research phase for the treatment of Ovarian cancer, breast cancer, and other solid tumors. Additionally, the company develops APL-1401 to treat moderately to severely active ulcerative colitis, ASN-1202 to treat free-living amebic infection, and APL-2301 for the treatment of Acinetobacter baumannii Infections. The company also offers TIMIN platform, a targeted immune regulation normalization technology platform for the development of new drugs for tumor immunotherapy and autoimmune diseases, TAIDD, a drug discovery platform that integrates physical modeling and artificial intelligence technologies, including core functional modules for target-based drug discovery, and DDC, a drug-device combination platform to deliver diagnostic or therapeutic drugs for the target site to reduce the systemic exposure of the drug. Jiangsu Yahong Meditech Co., Ltd. was founded in 2010 and is based in Shanghai, China.

Contact Information

Address Building B, Qiantan World Trade Center 19th Floor, Phase III
No. 11, Lane 221, Dongyu Road Pudong New Area Shanghai,200126
China
Phone 86 21 6858 3863
Fax 86 21 6858 5281

Top Executives

Name Age Since Title
Mingyuan Yang 41 2020 Financial Manager, Director & Board Secretary
Bin Huang 58 2020 Independent Director
Bing Hui Zhang 62 2020 Independent Director
Wenning Wang 57 2023 Independent Director
Chengfeng Zhuang 62 2019 Deputy GM & Director
Xianxian Li 36 2020 Director
Badrinath Konety - 2022 Member of Scientific Advisory Board
Joseph Liao - 2024 Member of the Advisory Board
Runlei Zhang 41 2023 Supervisor
Wende Chen 62 2023 Director
Jiani Kang 32 2023 Supervisor
Yi Zhong 52 2020 Employee Representative Chairman of the Supervisory Board
Neal D. Shore - 2024 Member of the Advisory Board
Xinming Jiang 55 2021 Senior VP, Head of Oncology Division & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

688176 Comments

Write your thoughts about Jiangsu Asieris Pharmaceuticals Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email